{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:39:05Z","timestamp":1790199545642,"version":"4.1.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40256-019-00328-6","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T21:46:54Z","timestamp":1550785614000},"page":"349-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pharmacotherapy of Obesity: Limits and Perspectives"],"prefix":"10.1007","volume":"19","author":[{"given":"Pamela","family":"Rosa-Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7916-5315","authenticated-orcid":false,"given":"David","family":"Majerowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"328_CR1","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/S0140-6736(16)00271-3","volume":"387","author":"GA Bray","year":"2016","unstructured":"Bray GA, Fr\u00fchbeck G, Ryan DH, Wilding JPH. Management of obesity. Lancet. 2016;387:1947\u201356.","journal-title":"Lancet"},{"key":"328_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2458-9-88","volume":"9","author":"DP Guh","year":"2009","unstructured":"Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.","journal-title":"BMC Public Health"},{"key":"328_CR3","first-page":"673","volume":"33","author":"A Hruby","year":"2015","unstructured":"Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacogenomics. 2015;33:673\u201389.","journal-title":"Pharmacogenomics"},{"key":"328_CR4","doi-asserted-by":"publisher","first-page":"e68785","DOI":"10.1371\/journal.pone.0068785","volume":"8","author":"K Rtveladze","year":"2013","unstructured":"Rtveladze K, Marsh T, Webber L, Kilpi F, Levy D, Conde W, et al. Health and economic burden of obesity in Brazil. PLoS One. 2013;8:e68785.","journal-title":"PLoS One"},{"key":"328_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/oby.2000.32","volume":"8","author":"IL Mertens","year":"2000","unstructured":"Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res. 2000;8:270\u20138.","journal-title":"Obes Res"},{"key":"328_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/sj.ejcn.1601375","volume":"56","author":"HH Ditschuneit","year":"2002","unstructured":"Ditschuneit HH, Frier HI, Flechtner-Mors M. Lipoprotein responses to weight loss and weight maintenance in high-risk obese subjects. Eur J Clin Nutr. 2002;56:264\u201370.","journal-title":"Eur J Clin Nutr"},{"key":"328_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.giec.2016.12.008","volume":"27","author":"D Umashanker","year":"2017","unstructured":"Umashanker D, Igel LI, Kumar RB, Aronne LJ. Current and future medical treatment of obesity. Gastrointest Endosc Clin N Am. 2017;27:181\u201390.","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"328_CR8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.neuron.2017.06.014","volume":"95","author":"ML Andermann","year":"2017","unstructured":"Andermann ML, Lowell BB. Toward a wiring diagram understanding of appetite control. Neuron. 2017;95:757\u201378.","journal-title":"Neuron"},{"key":"328_CR9","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1002\/oby.21771","volume":"25","author":"PS MacLean","year":"2017","unstructured":"MacLean PS, Blundell JE, Mennella JA, Batterham RL. Biological control of appetite: a daunting complexity. Obesity (Silver Spring). 2017;25:S8\u201316.","journal-title":"Obesity (Silver Spring)"},{"key":"328_CR10","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1042\/CS20160006","volume":"130","author":"M Hopkins","year":"2016","unstructured":"Hopkins M, Blundell JE. Energy balance, body composition, sedentariness and appetite regulation: pathways to obesity. Clin Sci. 2016;130:1615\u201328.","journal-title":"Clin Sci"},{"key":"328_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.coph.2017.09.002","volume":"37","author":"LK Heisler","year":"2017","unstructured":"Heisler LK, Lam DD. An appetite for life: brain regulation of hunger and satiety. Curr Opin Pharmacol. 2017;37:100\u20136.","journal-title":"Curr Opin Pharmacol"},{"key":"328_CR12","first-page":"9","volume":"19","author":"JA Bianchini","year":"2012","unstructured":"Bianchini JA, Hintze LJ, Bevilaqua C, Agnolo CMD, Nardo N. Tratamento da Obesidade: revis\u00e3o de artigos sobre interven\u00e7\u00f5es multiprofissionais no contexto brasileiro. Arq Ci\u00ea Sa\u00fade. 2012;19:9\u201315.","journal-title":"Arq Ci\u00ea Sa\u00fade"},{"key":"328_CR13","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1200\/JCO.2016.66.8806","volume":"34","author":"N Alamuddin","year":"2016","unstructured":"Alamuddin N, Bakizada Z, Wadden TA. Management of obesity. J Clin Oncol. 2016;34:4295\u2013305.","journal-title":"J Clin Oncol"},{"key":"328_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40608-017-0147-3","volume":"4","author":"FA Cadegiani","year":"2017","unstructured":"Cadegiani FA, Diniz GC, Alves G. Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience. BMC Obes. 2017;4:9.","journal-title":"BMC Obes"},{"key":"328_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.neubiorev.2016.08.026","volume":"76","author":"RJ Rodgers","year":"2017","unstructured":"Rodgers RJ. Bench to bedside in appetite research: lost in translation? Neurosci Biobehav Rev. 2017;76:163\u201373.","journal-title":"Neurosci Biobehav Rev"},{"key":"328_CR16","first-page":"137","volume":"36","author":"IIF Negreiros","year":"2011","unstructured":"Negreiros IIF, Oliveira DC, Figueredo MRO, Ferraz DLM, Souza LS, Moreira J, et al. Side effects and contraindications of anti-obesity drugs: a systematic review. Nutrire. 2011;36:137\u201360.","journal-title":"Nutrire"},{"key":"328_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1590\/1806-9282.63.03.203","volume":"63","author":"RC Lucchetta","year":"2017","unstructured":"Lucchetta RC, Riveros BS, Pontarolo R, Radominski RB, Otuki MF, Fernandez-Limos F, et al. Diethylpropion and mazindol: an end to the discussion? Rev Assoc Med Bras. 2017;63:203\u20136.","journal-title":"Rev Assoc Med Bras"},{"key":"328_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.6061\/clinics\/2017(05)10","volume":"72","author":"RC Lucchetta","year":"2017","unstructured":"Lucchetta RC, Riveros BS, Pontarolo R, Radominski RB, Otuki MF, Fernandez-Limos F, et al. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clin (S\u00e3o Paulo). 2017;72:317\u201324.","journal-title":"Clin (S\u00e3o Paulo)"},{"key":"328_CR19","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/ijo.2013.225","volume":"38","author":"H Suplicy","year":"2014","unstructured":"Suplicy H, Boguszewski CL, dos Santos CM, do Desterro de Figueiredo M, Cunha DR, Radominski R. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. Int J Obes. 2014;38:1097\u2013103.","journal-title":"Int J Obes"},{"key":"328_CR20","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1590\/S0104-42302011000500017","volume":"57","author":"MC Martins","year":"2011","unstructured":"Martins MC, Souza Filho MD, Moura FS, Carvalho JS, M\u00fcller MC, Neves RV, et al. Use of anti-obesity drugs among college students. Rev Assoc Med Bras. 2011;57:570\u20136.","journal-title":"Rev Assoc Med Bras"},{"key":"328_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1124\/pr.59.2.2","volume":"59","author":"GA Bray","year":"2007","unstructured":"Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007;59:151\u201384.","journal-title":"Pharmacol Rev"},{"key":"328_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bbr.2014.08.065","volume":"277","author":"JP Voigt","year":"2015","unstructured":"Voigt JP, Fink H. Serotonin controlling feeding and satiety. Behav Brain Res. 2015;277:14\u201331.","journal-title":"Behav Brain Res"},{"key":"328_CR23","first-page":"CD007654","volume":"3","author":"A Siebenhofer","year":"2016","unstructured":"Siebenhofer A, Jeitler K, Horvath K, Berghold A, Posch N, Meschik J, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev. 2016;3:CD007654.","journal-title":"Cochrane Database Syst Rev"},{"key":"328_CR24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","volume":"27","author":"R Padwal","year":"2003","unstructured":"Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003;27:1437\u201346.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"328_CR25","first-page":"CD004094","volume":"3","author":"RS Padwal","year":"2004","unstructured":"Padwal RS, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004;3:CD004094.","journal-title":"Cochrane Database Syst Rev"},{"key":"328_CR26","doi-asserted-by":"publisher","first-page":"e39062","DOI":"10.1371\/journal.pone.0039062","volume":"7","author":"YH Zhou","year":"2012","unstructured":"Zhou YH, Ma XQ, Wu C, Lu J, Zhang SS, Guo J, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2012;7:e39062.","journal-title":"PLoS One"},{"key":"328_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/sj.ijo.0802591","volume":"28","author":"JK Kaukua","year":"2004","unstructured":"Kaukua JK, Pekkarinen TA, Rissanen AM. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes Relat Metab Disord. 2004;28:600\u20135.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"328_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/sj.jhh.1001298","volume":"16","author":"FG McMahon","year":"2002","unstructured":"McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens. 2002;16:5\u201311.","journal-title":"J Hum Hypertens"},{"key":"328_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WP James","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905\u201317.","journal-title":"N Engl J Med"},{"key":"328_CR30","doi-asserted-by":"publisher","first-page":"18452","DOI":"10.4238\/2015.December.23.33","volume":"14","author":"RP Araldi","year":"2015","unstructured":"Araldi RP, Santos NP, Mendes TB, Carvalho LB, Ito ET, de-S\u00e1-J\u00fanior PL, et al. Can spirulina maxima reduce the mutagenic potential of sibutramine? Genet Mol Res. 2015;14:18452\u201364.","journal-title":"Genet Mol Res"},{"key":"328_CR31","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4070\/kcj.2013.43.9.632","volume":"43","author":"SH Heo","year":"2013","unstructured":"Heo SH, Kang MH. A case of dilated cardiomyopathy with massive left ventricular thrombus after use of a sibutramine-containing slimming product. Korean Circ J. 2013;43:632\u20135.","journal-title":"Korean Circ J"},{"key":"328_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0014-2999(02)01422-X","volume":"440","author":"A Ballinger","year":"2002","unstructured":"Ballinger A, Peikin SR. Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol. 2002;440:109\u201317.","journal-title":"Eur J Pharmacol"},{"key":"328_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/diacare.27.1.155","volume":"27","author":"JS Torgerson","year":"2004","unstructured":"Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155\u201361.","journal-title":"Diabetes Care"},{"key":"328_CR34","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/archinte.168.6.571","volume":"168","author":"K Horvath","year":"2008","unstructured":"Horvath K, Jeitler K, Siering U, Stich AK, Skipka G, Gratzer TW, et al. Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis. Arch Intern Med. 2008;168:571\u201380.","journal-title":"Arch Intern Med"},{"key":"328_CR35","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ Clin Res. 2007;335:1194\u20139.","journal-title":"BMJ Clin Res"},{"key":"328_CR36","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/ajcn\/80.6.1461","volume":"80","author":"B Hutton","year":"2004","unstructured":"Hutton B, Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr. 2004;80:1461\u20138.","journal-title":"Am J Clin Nutr"},{"key":"328_CR37","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1038\/oby.2007.323","volume":"15","author":"MJ Perrio","year":"2007","unstructured":"Perrio MJ, Wilton LV, Shakir SA. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity. 2007;15:2712\u201322.","journal-title":"Obesity"},{"key":"328_CR38","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1467-789X.2004.00125.x","volume":"5","author":"S O\u2019Meara","year":"2004","unstructured":"O\u2019Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev. 2004;5:51\u201368.","journal-title":"Obes Rev"},{"key":"328_CR39","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1345\/aph.1C122","volume":"37","author":"RS MacWalter","year":"2003","unstructured":"MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother. 2003;37:510\u20132.","journal-title":"Ann Pharmacother"},{"key":"328_CR40","doi-asserted-by":"publisher","first-page":"e6721","DOI":"10.5812\/ijem.6721","volume":"11","author":"D Palacios-Martinez","year":"2013","unstructured":"Palacios-Martinez D, Garcia-Alvarez JC, Montero-Santamaria N, Villar-Ruiz OP, Ruiz-Garcia A, Diaz-Alonso RA. Macrocytic anemia and thrombocytopenia induced by orlistat. Int J Endocrinol Metab. 2013;11:e6721.","journal-title":"Int J Endocrinol Metab"},{"key":"328_CR41","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.genhosppsych.2014.05.006","volume":"36","author":"KS Deb","year":"2014","unstructured":"Deb KS, Gupta R, Varshney M. Orlistat abuse in a case of bulimia nervosa: the changing Indian society. Gen Hosp Psychiatry. 2014;36:e3\u20134.","journal-title":"Gen Hosp Psychiatry"},{"key":"328_CR42","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1124\/jpet.107.133348","volume":"325","author":"WJ Thomsen","year":"2008","unstructured":"Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-saldana H, Espitia S, Yuskin D, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine 2C agonist: in vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577\u201387.","journal-title":"J Pharmacol Exp Ther"},{"key":"328_CR43","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1210\/en.2007-1321","volume":"149","author":"DD Lam","year":"2008","unstructured":"Lam DD, Przydzial MJ, Ridley SH, Yeo GS, Rochford JJ, O\u2019Rahilly S, et al. Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. Endocrinology. 2008;149:1323\u20138.","journal-title":"Endocrinology"},{"key":"328_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2174\/1568026023393796","volume":"2","author":"WK Kroeze","year":"2002","unstructured":"Kroeze WK, Kristiansen K, Roth BL. Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem. 2002;2:507\u201328.","journal-title":"Curr Top Med Chem"},{"key":"328_CR45","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131\u201381.","journal-title":"Pharmacol Ther"},{"key":"328_CR46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/MJT.0b013e31817fde95","volume":"16","author":"RB Rothman","year":"2009","unstructured":"Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther. 2009;16:354\u201364.","journal-title":"Am J Ther"},{"key":"328_CR47","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/obr.12015","volume":"14","author":"EW Chan","year":"2013","unstructured":"Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev. 2013;14:383\u201392.","journal-title":"Obes Rev"},{"key":"328_CR48","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/oby.2012.66","volume":"20","author":"PMM O\u2019Neil","year":"2012","unstructured":"O\u2019Neil PMM, Smith SRR, Weissman NJJ, Fidler MCC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426\u201336.","journal-title":"Obesity"},{"key":"328_CR49","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1080\/00325481.2016.1178590","volume":"128","author":"R Nesto","year":"2016","unstructured":"Nesto R, Fain R, Li Y, Shanahan W. Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia. Postgrad Med. 2016;128:364\u201370.","journal-title":"Postgrad Med"},{"key":"328_CR50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJMoa0909809","volume":"363","author":"SR Smith","year":"2010","unstructured":"Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245\u201356.","journal-title":"N Engl J Med"},{"key":"328_CR51","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1210\/jc.2011-1256","volume":"96","author":"MC Fidler","year":"2011","unstructured":"Fidler MC, Sanchez M, Raether B, Weissman NJ, Smith SR, Shanahan WR, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067\u201377.","journal-title":"J Clin Endocrinol Metab"},{"key":"328_CR52","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1053\/j.gastro.2016.12.049","volume":"152","author":"LI Igel","year":"2017","unstructured":"Igel LI, Kumar RB, Saunders KH, Aronne LJ. Practical use of pharmacotherapy for obesity. Gastroenterology. 2017;152:1765\u201379.","journal-title":"Gastroenterology"},{"key":"328_CR53","first-page":"1","volume":"5","author":"B Bai","year":"2010","unstructured":"Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des Dev Ther. 2010;5:1\u20137.","journal-title":"Drug Des Dev Ther"},{"key":"328_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/14740338.2017.1247807","volume":"16","author":"B Halpern","year":"2017","unstructured":"Halpern B, Mancini MC. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone\/bupropion extended release and phentermine\u2013topiramate extended release. Expert Opin Drug Saf. 2017;16:27\u201339.","journal-title":"Expert Opin Drug Saf"},{"key":"328_CR55","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.pharmthera.2016.10.015","volume":"170","author":"V Narayanaswami","year":"2017","unstructured":"Narayanaswami V, Dwoskin LP. Obesity: current and potential pharmacotherapeutics and targets. Pharmacol Ther. 2017;170:116\u201347.","journal-title":"Pharmacol Ther"},{"key":"328_CR56","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1053\/j.gastro.2014.11.020","volume":"148","author":"A Acosta","year":"2015","unstructured":"Acosta A, Camilleri M, Shin A, Vazquez-Roque MI, Iturrino J, Burton D, et al. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology. 2015;148:537\u201346.","journal-title":"Gastroenterology"},{"key":"328_CR57","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341\u201352.","journal-title":"Lancet"},{"key":"328_CR58","doi-asserted-by":"publisher","first-page":"912","DOI":"10.2337\/dc13-1518","volume":"37","author":"WT Garvey","year":"2014","unstructured":"Garvey WT, Ryan DH, Henry R, Bohannon NJ, Toplak H, Schwiers M, et al. Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care. 2014;37:912\u201321.","journal-title":"Diabetes Care"},{"key":"328_CR59","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.5665\/sleep.2204","volume":"35","author":"DH Winslow","year":"2012","unstructured":"Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine\/topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep. 2012;35:1529\u201339.","journal-title":"Sleep"},{"key":"328_CR60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297\u2013308.","journal-title":"Am J Clin Nutr"},{"key":"328_CR61","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity. 2012;20:330\u201342.","journal-title":"Obesity"},{"key":"328_CR62","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.2337\/dc14-0930","volume":"37","author":"WT Garvey","year":"2014","unstructured":"Garvey WT, Ryan DH, Bohannon NJ, Kushner RF, Rueger M, Dvorak RV, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014;37:3309\u201316.","journal-title":"Diabetes Care"},{"key":"328_CR63","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/dom.12502","volume":"17","author":"K Fujioka","year":"2015","unstructured":"Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab. 2015;17:1021\u201332.","journal-title":"Diabetes Obes Metab"},{"key":"328_CR64","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2174\/1389450118666170227153940","volume":"18","author":"SP Bhat","year":"2017","unstructured":"Bhat SP, Sharma A. Current drug targets in obesity pharmacotherapy\u2014a review. Curr Drug Targets. 2017;18:983\u201393.","journal-title":"Curr Drug Targets"},{"key":"328_CR65","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/jm9909645","volume":"43","author":"LB Knudsen","year":"2000","unstructured":"Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000;43:1664\u20139.","journal-title":"J Med Chem"},{"key":"328_CR66","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.mce.2008.11.018","volume":"297","author":"D Russell-Jones","year":"2009","unstructured":"Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009;297:137\u201340.","journal-title":"Mol Cell Endocrinol"},{"key":"328_CR67","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1463-1326.2012.01673.x","volume":"15","author":"K Niswender","year":"2013","unstructured":"Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013;15:42\u201354.","journal-title":"Diabetes Obes Metab"},{"key":"328_CR68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13098-017-0242-0","volume":"9","author":"MC Mancini","year":"2017","unstructured":"Mancini MC, de Melo ME. The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0\u00a0mg. Diabetol Metab Syndr. 2017;9:44.","journal-title":"Diabetol Metab Syndr"},{"key":"328_CR69","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/1753-0407.12198","volume":"7","author":"F Zhang","year":"2015","unstructured":"Zhang F, Tong Y, Su N, Li Y, Tang L, Huang L, et al. Weight loss effect of glucagon-like peptide-1 mimetics on obese\/overweight adults without diabetes: a systematic review and meta-analysis of randomized controlled trials. J Diabetes. 2015;7:329\u201339.","journal-title":"J Diabetes"},{"key":"328_CR70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0\u00a0mg of liraglutide in weight management. N Engl J Med. 2015;373:11\u201322.","journal-title":"N Engl J Med"},{"key":"328_CR71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/oby.2008.461","volume":"17","author":"FL Greenway","year":"2009","unstructured":"Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009;17:30\u20139.","journal-title":"Obesity"},{"key":"328_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2014.04.004","volume":"84","author":"SK Billes","year":"2014","unstructured":"Billes SK, Sinnayah P, Cowley MA. Naltrexone\/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1\u201311.","journal-title":"Pharmacol Res"},{"key":"328_CR73","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/oby.21726","volume":"25","author":"A Halseth","year":"2017","unstructured":"Halseth A, Shan K, Walsh B, Gilder K, Fujioka K. Method-of-use study of naltrexone sustained release (SR)\/bupropion SR on body weight in individuals with obesity. Obesity. 2017;25:338\u201345.","journal-title":"Obesity"},{"key":"328_CR74","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"TA Wadden","year":"2011","unstructured":"Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O\u2019Neil PM, et al. Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity. 2011;19:110\u201320.","journal-title":"Obesity"},{"key":"328_CR75","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"P Hollander","year":"2013","unstructured":"Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022\u20139.","journal-title":"Diabetes Care"},{"key":"328_CR76","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"CM Apovian","year":"2013","unstructured":"Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity. 2013;21:935\u201343.","journal-title":"Obesity"},{"key":"328_CR77","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cob.12157","volume":"6","author":"K Hong","year":"2016","unstructured":"Hong K, Herrmann K, Dybala C, Halseth AE, Lam H, Foreyt JP. Naltrexone\/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clin Obes. 2016;6:305\u201312.","journal-title":"Clin Obes"},{"key":"328_CR78","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"FL Greenway","year":"2010","unstructured":"Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595\u2013605.","journal-title":"Lancet"},{"key":"328_CR79","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1242\/dmm.026609","volume":"10","author":"K Timper","year":"2017","unstructured":"Timper K, Br\u00fcning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech. 2017;10:679\u201389.","journal-title":"Dis Model Mech"},{"key":"328_CR80","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/npp.2010.16","volume":"35","author":"AM Axel","year":"2010","unstructured":"Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010;35:1464\u201376.","journal-title":"Neuropsychopharmacology"},{"key":"328_CR81","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejphar.2010.03.026","volume":"636","author":"HH Hansen","year":"2010","unstructured":"Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A, et al. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010;636:88\u201395.","journal-title":"Eur J Pharmacol"},{"key":"328_CR82","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pbb.2013.07.018","volume":"110","author":"HH Hansen","year":"2013","unstructured":"Hansen HH, Jensen MM, Overgaard A, Weikop P, Mikkelsen JD. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacol Biochem Behav. 2013;110:265\u201371.","journal-title":"Pharmacol Biochem Behav"},{"key":"328_CR83","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.euroneuro.2011.07.015","volume":"22","author":"E Giessen van de","year":"2012","unstructured":"van de Giessen E, de Bruin K, la Fleur SE, van den Brink W, Booij J. Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2\/D3 receptor availability in diet-induced obese rats. Eur Neuropsychopharmacol. 2012;22:290\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"key":"328_CR84","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/mds.21258","volume":"22","author":"RA Hauser","year":"2007","unstructured":"Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson\u2019s disease. Mov Disord. 2007;22:359\u201365.","journal-title":"Mov Disord"},{"key":"328_CR85","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/S0140-6736(08)61525-1","volume":"372","author":"A Astrup","year":"2008","unstructured":"Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1906\u201313.","journal-title":"Lancet"},{"key":"328_CR86","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1038\/ijo.2010.87","volume":"34","author":"A Sj\u00f6din","year":"2010","unstructured":"Sj\u00f6din A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes. 2010;34:1634\u201343.","journal-title":"Int J Obes"},{"key":"328_CR87","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/oby.2008.56","volume":"16","author":"A Astrup","year":"2008","unstructured":"Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson\u2019s or Alzheimer\u2019s disease. Obesity. 2008;16:1363\u20139.","journal-title":"Obesity"},{"key":"328_CR88","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/archneur.65.5.577","volume":"65","author":"O Rascol","year":"2008","unstructured":"Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS study. Arch Neurol. 2008;65:577\u201383.","journal-title":"Arch Neurol"},{"key":"328_CR89","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/oby.20122","volume":"21","author":"BH Bentzen","year":"2013","unstructured":"Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, Lassen JB, Hansen HH. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity. 2013;21:985\u201392.","journal-title":"Obesity"},{"key":"328_CR90","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/clpt.2010.67","volume":"88","author":"KA Schoedel","year":"2010","unstructured":"Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010;88:69\u201378.","journal-title":"Clin Pharmacol Ther"},{"key":"328_CR91","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/mp.2011.29","volume":"16","author":"EA Rabiner","year":"2011","unstructured":"Rabiner EA, Beaver J, Makwana A, Searle G, Long C, Nathan PJ, et al. Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. Mol Psychiatry. 2011;16:826\u201335.","journal-title":"Mol Psychiatry"},{"key":"328_CR92","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1124\/jpet.111.180943","volume":"339","author":"DM Ignar","year":"2011","unstructured":"Ignar DM, Goetz AS, Noble KN, Carballo LH, Stroup AE, Fisher JC, et al. Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist. J Pharmacol Exp Ther. 2011;339:24\u201334.","journal-title":"J Pharmacol Exp Ther"},{"key":"328_CR93","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1038\/npp.2012.128","volume":"37","author":"C Giuliano","year":"2012","unstructured":"Giuliano C, Robbins TW, Nathan PJ, Bullmore ET, Everitt BJ. Inhibition of opioid transmission at the \u03bc-opioid receptor prevents both food seeking and binge-like eating. Neuropsychopharmacology. 2012;37:2643\u201352.","journal-title":"Neuropsychopharmacology"},{"key":"328_CR94","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1177\/0091270011399577","volume":"52","author":"PJ Nathan","year":"2012","unstructured":"Nathan PJ, O\u2019Neill BV, Bush MA, Koch A, Tao WX, Maltby K, et al. Opioid receptor modulation of hedonic taste preference and food intake: a single-dose safety, pharmacokinetic, and pharmacodynamic investigation with GSK1521498, a novel \u03bc-opioid receptor inverse agonist. J Clin Pharmacol. 2012;52:464\u201374.","journal-title":"J Clin Pharmacol"},{"key":"328_CR95","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1177\/0091270011421785","volume":"52","author":"PJ Nathan","year":"2012","unstructured":"Nathan PJ, Bush MA, Tao WX, Koch A, Davies KM, Maltby K, et al. Multiple-dose safety, pharmacokinetics, and pharmacodynamics of the \u03bc-opioid receptor inverse agonist GSK1521498. J Clin Pharmacol. 2012;52:1456\u201367.","journal-title":"J Clin Pharmacol"},{"key":"328_CR96","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/mp.2012.154","volume":"18","author":"H Ziauddeen","year":"2013","unstructured":"Ziauddeen H, Chamberlain SR, Nathan PJ, Koch A, Maltby K, Bush M, et al. Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. Mol Psychiatry. 2013;18:1287\u201393.","journal-title":"Mol Psychiatry"},{"key":"328_CR97","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00213-012-2778-x","volume":"224","author":"SR Chamberlain","year":"2012","unstructured":"Chamberlain SR, Mogg K, Bradley BP, Koch A, Dodds CM, Tao WX, et al. Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals. Psychopharmacology. 2012;224:501\u20139.","journal-title":"Psychopharmacology"},{"key":"328_CR98","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.biopsych.2012.10.022","volume":"73","author":"VC Cambridge","year":"2013","unstructured":"Cambridge VC, Ziauddeen H, Nathan PJ, Subramaniam N, Dodds C, Chamberlain SR, et al. Neural and behavioral effects of a novel mu opioid receptor antagonist in binge-eating obese people. Biol Psychiatry. 2013;73:887\u201394.","journal-title":"Biol Psychiatry"},{"key":"328_CR99","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/MCO.0b013e328365b9be","volume":"16","author":"G Pradhan","year":"2013","unstructured":"Pradhan G, Samson SL, Sun Y. Ghrelin: much more than a hunger hormone. Curr Opin Clin Nutr Metab Care. 2013;16:619\u201324.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"328_CR100","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000346059","volume":"25","author":"PJ Delhanty","year":"2013","unstructured":"Delhanty PJ, Neggers SJ, van der Lely AJ. Des-acyl ghrelin: a metabolically active peptide. Endocr Dev. 2013;25:112\u201321.","journal-title":"Endocr Dev"},{"key":"328_CR101","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ijpo.12177","volume":"13","author":"MJ Khan","year":"2018","unstructured":"Khan MJ, Gerasimidis K, Edwards CA, Shaikh MG. Mechanisms of obesity in Prader\u2013Willi syndrome. Pediatr Obes. 2018;13:3\u201313.","journal-title":"Pediatr Obes"},{"key":"328_CR102","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1096\/fj.12-221143","volume":"27","author":"PJ Delhanty","year":"2013","unstructured":"Delhanty PJ, Huisman M, Baldeon-Rojas LY, van den Berge I, Grefhorst A, Abribat T, et al. Des-acyl ghrelin analogs prevent high-fat-diet-induced dysregulation of glucose homeostasis. FASEB J. 2013;27:1690\u2013700.","journal-title":"FASEB J."},{"key":"328_CR103","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/dom.12675","volume":"18","author":"S Allas","year":"2016","unstructured":"Allas S, Delale T, Ngo N, Julien M, Sahakian P, Ritter J, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight\/obese subjects and subjects with type 2 diabetes. Diabetes Obes Metab. 2016;18:868\u201374.","journal-title":"Diabetes Obes Metab"},{"key":"328_CR104","doi-asserted-by":"publisher","first-page":"e0190849","DOI":"10.1371\/journal.pone.0190849","volume":"13","author":"S Allas","year":"2018","unstructured":"Allas S, Caix\u00e0s A, Poitou C, Coupaye M, Thuilleaux D, Lorenzini F, et al. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader\u2013Willi syndrome: a randomized placebo-controlled trial. PLoS One. 2018;13:e0190849.","journal-title":"PLoS One"},{"key":"328_CR105","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.plipres.2011.02.002","volume":"50","author":"JE Stewart","year":"2011","unstructured":"Stewart JE, Feinle-Bisset C, Keast RS. Fatty acid detection during food consumption and digestion: associations with ingestive behavior and obesity. Prog Lipid Res. 2011;50:225\u201333.","journal-title":"Prog Lipid Res"},{"key":"328_CR106","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1055\/s-2008-1076699","volume":"40","author":"Y Yamada","year":"2008","unstructured":"Yamada Y, Kato T, Ogino H, Ashina S, Kato K. Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats. Horm Metab Res. 2008;40:539\u201343.","journal-title":"Horm Metab Res"},{"key":"328_CR107","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.ijo.0803446","volume":"31","author":"P Kopelman","year":"2007","unstructured":"Kopelman P, Bryson A, Hickling R, Rissanen A, Rossner S, Toubro S, et al. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes. 2007;31:494\u20139.","journal-title":"Int J Obes"},{"key":"328_CR108","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/oby.2009.155","volume":"18","author":"P Kopelman","year":"2010","unstructured":"Kopelman P, Groot GH, Rissanen A, Rossner S, Toubro S, Palmer R, et al. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity. 2010;18:108\u201315.","journal-title":"Obesity"},{"key":"328_CR109","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1365-2125.2008.03311.x","volume":"67","author":"A Bryson","year":"2009","unstructured":"Bryson A, de la Motte S, Dunk C. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers. Br J Clin Pharmacol. 2009;67:309\u201315.","journal-title":"Br J Clin Pharmacol"},{"key":"328_CR110","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jpba.2014.07.026","volume":"100","author":"M Johansson","year":"2014","unstructured":"Johansson M, Fransson D, Rundl\u00f6f T, Huynh NH, Arvidsson T. A general analytical platform and strategy in search for illegal drugs. J Pharm Biomed Anal. 2014;100:215\u201329.","journal-title":"J Pharm Biomed Anal"},{"key":"328_CR111","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/obr.12530","volume":"18","author":"Y Duan","year":"2017","unstructured":"Duan Y, Li F, Tan B, Yao K, Yin Y. Metabolic control of myofibers: promising therapeutic target for obesity and type 2 diabetes. Obes Res. 2017;18:647\u201359.","journal-title":"Obes Res"},{"key":"328_CR112","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1042\/CS20150339","volume":"129","author":"L Poekes","year":"2015","unstructured":"Poekes L, Lanthier N, Leclercq IA. Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome. Clin Sci. 2015;129:933\u201349.","journal-title":"Clin Sci"},{"key":"328_CR113","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000353254","volume":"99","author":"Y Cao","year":"2014","unstructured":"Cao Y. Angiogenesis as a therapeutic target for obesity and metabolic diseases. Chem Immunol Allergy. 2014;99:170\u20139.","journal-title":"Chem Immunol Allergy"},{"key":"328_CR114","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nm1048","volume":"10","author":"MG Kolonin","year":"2004","unstructured":"Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10:625\u201332.","journal-title":"Nat Med"},{"key":"328_CR115","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2337\/db09-1141","volume":"59","author":"DH Kim","year":"2010","unstructured":"Kim DH, Woods SC, Seeley RJ. Peptide designed to elicit apoptosis in adipose tissue endothelium reduces food intake and body weight. Diabetes. 2010;59:907\u201315.","journal-title":"Diabetes"},{"key":"328_CR116","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.2337\/db11-1579","volume":"61","author":"DH Kim","year":"2012","unstructured":"Kim DH, Sartor MA, Bain JR, Sandoval D, Stevens RD, Medvedovic M, et al. Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium. Diabetes. 2012;61:2299\u2013310.","journal-title":"Diabetes"},{"key":"328_CR117","doi-asserted-by":"publisher","first-page":"108ra112","DOI":"10.1126\/scitranslmed.3002621","volume":"3","author":"KF Barnhart","year":"2011","unstructured":"Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011;3:108ra112.","journal-title":"Sci Transl Med."},{"key":"328_CR118","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jconrel.2013.07.013","volume":"171","author":"N Hossen","year":"2013","unstructured":"Hossen N, Kajimoto K, Akita H, Hyodo M, Harashima H. A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. J Control Release. 2013;171:104\u201312.","journal-title":"J Control Release"},{"key":"328_CR119","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/oby.2012.59","volume":"20","author":"JJ Devenny","year":"2012","unstructured":"Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity. 2012;20:1645\u201352.","journal-title":"Obesity"},{"key":"328_CR120","doi-asserted-by":"publisher","first-page":"e0150756","DOI":"10.1371\/journal.pone.0150756","volume":"11","author":"Y Chiba","year":"2016","unstructured":"Chiba Y, Yamada T, Tsukita S, Takahashi K, Munakata Y, Shirai Y, et al. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice. PLoS One. 2016;11:e0150756.","journal-title":"PLoS One"},{"key":"328_CR121","doi-asserted-by":"publisher","first-page":"E137","DOI":"10.3390\/ijms19010137","volume":"19","author":"D Wang","year":"2018","unstructured":"Wang D, Luo Y, Wang X, Orlicky DJ, Myakala K, Yang P, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in western diet induced obesity mice. Int J Mol Sci. 2018;19:E137.","journal-title":"Int J Mol Sci"},{"key":"328_CR122","doi-asserted-by":"publisher","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","volume":"9","author":"N Terami","year":"2014","unstructured":"Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PLoS One. 2014;9:e100777.","journal-title":"PLoS One"},{"key":"328_CR123","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/dmrr.2479","volume":"30","author":"M Zhang","year":"2014","unstructured":"Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30:204\u201321.","journal-title":"Diabetes Metab Res Rev"},{"key":"328_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21020","volume":"21","author":"R Johnston","year":"2017","unstructured":"Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess (Rockv). 2017;21:1\u2013218.","journal-title":"Health Technol Assess (Rockv)"},{"key":"328_CR125","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/osp4.46","volume":"2","author":"S Zhang","year":"2016","unstructured":"Zhang S, Manne S, Lin J, Yang J. Characteristics of patients potentially eligible for pharmacotherapy for weight loss in primary care practice in the United States. Obes Sci Pract. 2016;2:104\u201314.","journal-title":"Obes Sci Pract"},{"key":"328_CR126","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1758-8111.2011.00028.x","volume":"1","author":"S Sharma","year":"2011","unstructured":"Sharma S, Wharton S, Forhan M, Kuk JL. Influence of weight discrimination on weight loss goals and self-selected weight loss interventions. Clin Obes. 2011;1:153\u201360.","journal-title":"Clin Obes"},{"key":"328_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.orcp.2008.10.004","volume":"3","author":"TH Liou","year":"2009","unstructured":"Liou TH, Huang N, Wu CH, Chou YJ, Liou YM, Chou P. Weight loss behavior in obese patients before seeking professional treatment in Taiwan. Obes Res Clin Pract. 2009;3:1\u201352.","journal-title":"Obes Res Clin Pract"},{"key":"328_CR128","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1139\/apnm-2014-0549","volume":"40","author":"A Tremblay","year":"2015","unstructured":"Tremblay A, Bellisle F. Nutrients, satiety, and control of energy intake. Appl Physiol Nutr Metab. 2015;40:971\u20139.","journal-title":"Appl Physiol Nutr Metab"},{"key":"328_CR129","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","volume":"13","author":"S Kasichayanula","year":"2011","unstructured":"Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:357\u201365.","journal-title":"Diabetes Obes Metab"},{"key":"328_CR130","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/dom.12954","volume":"19","author":"P Lundkvist","year":"2017","unstructured":"Lundkvist P, Pereira MJ, Katsogiannos P, Sj\u00f6str\u00f6m CD, Johnsson E, Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: sustained reductions in body weight, glycaemia and blood pressure over 1 year. Diabetes Obes Metab. 2017;19:1276\u201388.","journal-title":"Diabetes Obes Metab"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-019-00328-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00328-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-019-00328-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T19:19:12Z","timestamp":1582312752000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-019-00328-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":130,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["328"],"URL":"https:\/\/doi.org\/10.1007\/s40256-019-00328-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"22 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by the Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq) and the Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro (FAPERJ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Pamela Rosa-Gon\u00e7alves and David Majerowicz have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}